Allergic Conjunctivitis Market, Size, Global Forecast 2024-2030, Industry Trends, Growth, Share, Companies Analysis
Allergic Conjunctivitis Market Outlook
Allergic Conjunctivitis Market is expected to reach US$ 1,642.6 Million by 2027. Allergic conjunctivitis interchangeably is also known as Ocular allergy (OA). It is a common immunological hypersensitivity disorder affecting numerous populations. In recent years, allergic conjunctivitis has been increasing in frequency, with symptoms of itching, redness, and swelling globally that significantly impact an individual’s quality of life. Besides, allergic conjunctivitis is an often under diagnosed and undertreated health problem because very few patients with allergic conjunctivitis symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary no pharmacological remedies.
Global Allergic Conjunctivitis Market Size was US$ 1,621.5 Million in 2021
Recently, the prevalence of allergic conjunctivitis has increased due to factors like rapid urbanization and an increasing number of allergens. Moreover, increasing awareness is further expected to boost the adoption of drugs for allergic conjunctivitis conditions during the forecast period. Remarkably, considering these contributively factors, a substantial influx of generic versions of prominent medications is likely to create growth opportunities for the global allergic conjunctivitis market during the forecast period. Furthermore, increasing prescription (Rx) drugs to over-the-counter (OTC) switches are also expected to boost this market.
United States dominates Global Allergic Conjunctivitis Market, Patients Population & Treated Patients Population
As per our analysis, the United States stands out as the largest market for allergic conjunctivitis treatments due to the high prevalence of allergic conjunctivitis. Further, the allergic conjunctivitis treatment market in the United States has the most dominant patient population and is also expected to have a large population base in the forecasted period. Remarkably, leading to increased demand for improved health care facilities, the country also has the most significant treated patients’ population.
Further, rapid urbanization and increased particulate pollution have augmented the incidence of allergic conjunctivitis in several countries, such as India and China. However, a few factors such as a dearth of awareness among the general public concerning eye disorders and lack of health insurance control the market in France, Germany, Italy, and Spain. According to Renub Research, Global Allergic Conjunctivitis Industry will grow with a CAGR of 0.2% from 2021-2027.
Impact of Coronavirus (COVID-19) Pandemic on Global Allergic Conjunctivitis Market
COVID-19 virus outbreak in December 2019 had spread to over 100 countries across the globe. Moreover, COVID-19 affected the economy in three significant ways; by directly affecting production and demand, devising disruptions in distribution channels, and its financial influence on firms and financial markets. Further, players operating in the worldwide allergic conjunctivitis industry faced significant challenges on various fronts due to the COVID-19 pandemic.
Nevertheless, significant challenges comprise the supply of raw materials required for drug formulations due to irregularities in transportation. Moreover, distributors also experienced irregular demand for products from the retailers due to the increased number of patients suffering from COVID-19 and other life-threatening disorders.
Allergic Conjunctivitis Associated with Medical Treatment & Upcoming Therapies Are Enhancing the Market Expansion
Our report covers numerous Disease Type variants like Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC), and Giant Papillary Conjunctivitis (GPC). Moreover, in our report, we have also covered, Allergic Conjunctivitis Pipeline Drugs like Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011. The increase in awareness of allergic conjunctivitis associated with medical treatment & upcoming therapies is enhancing the market expansion. Moreover, numerous pharmaceutical companies are trying to develop many new treatment possibilities for allergic conjunctivitis.
Key Market Players
Major players performing in the global allergic conjunctivitis market are Ocular Therapeutix Inc., Portola Pharmaceuticals Inc., Alcon, Santen Pharmaceutical Co., Ltd., and Novartis. Key players operating in the market are tremendously focusing on developing treatments for allergic conjunctivitis. This is anticipated to drive the global allergic conjunctivitis market growth during the forecast period.
Further, the market players are considerably contributing to market growth by adopting various strategies, including new product launches, mergers and acquisitions, collaborations with the government, and technological advancements to stay competitive in the market.
Renub Research report titled “Global Allergic Conjunctivitis Market, Patients, Treated Patients By Countries (India, China, Japan, United States, United Kingdom, France, Germany, Italy, Spain), Disease Type (Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Kerato Conjunctivitis (VKC), Atopic Kerato Conjunctivitis (AKC) And Giant Papillary Conjunctivitis (GPC)), Drugs Profile (Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011) Companies (Ocular Therapeutix Inc., Portola Pharmaceuticals Inc., Alcon, Santen Pharmaceutical Co., Ltd., and Novartis)” provides a detailed analysis of Allergic Conjunctivitis Industry.
Country – Market, Patient Numbers and Treated Patient Numbers breakup from 9 viewpoints:
1. India
2. China
3. Japan
4. United States
5. United Kingdom
6. France
7. Germany
8. Italy
9. Spain
Disease – Market Breakup from 4 viewpoints:
1. Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
2. Vernal Kerato Conjunctivitis (VKC)
3. Atopic Kerato Conjunctivitis (AKC)
4. Giant Papillary Conjunctivitis (GPC)
Drugs – Market Breakup from 10 viewpoints:
1. Zerviate
2. OTX-DP
3. ADX-102
4. PRT-2761
5. CVXL-0074
6. AK-002
7. Bertilimumab
8. Reproxalap
9. ST-266
10. SYL-116011
Company Insights:
• Overviews
• Recent Developments
• Revenues
Companies Covered:
1. Ocular Therapeutix Inc.
2. Portola Pharmaceuticals Inc.
3. Alcon
4. Santen Pharmaceutical Co., Ltd.
5. Novartis
Report Details:
| Report Features | Details |
| Base Year | 2021 |
| Historical Period | 2016 - 2021 |
| Forecast Period | 2022-2027 |
| Market | US$ Billion |
| Segment Covered | Country, Disease, Drugs |
| Country Covered | India, China, Japan, United States, United Kingdom, France, Germany, Italy, Spain |
| Companies Covered | Ocular Therapeutix Inc., Portola Pharmaceuticals Inc., Alcon, Santen Pharmaceutical Co., Ltd., and Novartis |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Frequently Asked Questions:
- What is the study period of Allergic Conjunctivitis Market?
- What is the growth rate of Allergic Conjunctivitis Market?
- What are the driving factors in Allergic Conjunctivitis Market?
- Which country has highest growth rate in Allergic Conjunctivitis Market?
- Which country has largest share in Allergic Conjunctivitis Market?
- Who are the key players in Allergic Conjunctivitis Market?
- What is the COVID-19 impact on Allergic Conjunctivitis Market?
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Allergic Conjunctivitis Market and Patients Analysis
5.1 Market
5.2 Patient Numbers
5.3 Treated Patient Numbers
6. Share Analysis - Global Allergic Conjunctivitis
6.1 Country Market Share
6.2 Patients Population Share
6.3 Treated Patients Population Share
6.4 By Disease Type Share
7. India – Allergic Conjunctivitis Analysis
7.1 Market
7.2 Patient Numbers
7.3 Treated Patient Numbers
8. China – Allergic Conjunctivitis Analysis
8.1 Market
8.2 Patient Numbers
8.3 Treated Patient Numbers
9. Japan – Allergic Conjunctivitis Analysis
9.1 Market
9.2 Patient Numbers
9.3 Treated Patient Numbers
10. United States – Allergic Conjunctivitis Analysis
10.1 Market
10.2 Patient Numbers
10.3 Treated Patient Numbers
11. United Kingdom – Allergic Conjunctivitis Analysis
11.1 Market
11.2 Patient Numbers
11.3 Treated Patient Numbers
12. France – Allergic Conjunctivitis Analysis
12.1 Market
12.2 Patient Numbers
12.3 Treated Patient Numbers
13. Germany – Allergic Conjunctivitis Analysis
13.1 Market
13.2 Patient Numbers
13.3 Treated Patient Numbers
14. Italy – Allergic Conjunctivitis Analysis
14.1 Market
14.2 Patient Numbers
14.3 Treated Patient Numbers
15. Spain – Allergic Conjunctivitis Analysis
15.1 Market
15.2 Patient Numbers
15.3 Treated Patient Numbers
16. Disease Type – Global Allergic Conjunctivitis Market
16.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC
16.2 Vernal Keratoconjunctivitis (VKC)
16.3 Atopic Keratoconjunctivitis (AKC)
16.4 Giant Papillary Conjunctivitis (GPC)
17. Global Allergic Conjunctivitis Pipeline Drugs
17.1 Zerviate
17.2 OTX-DP (Dexamethasone Insert)
17.3 ADX-102
17.4 PRT2761
17.5 CVXL-0074
17.6 AK-002
17.7 Bertilimumab
17.8 Reproxalap
17.9 ST-266
17.10 SYL-116011
18. Porters Five Forces
18.1 Overview
18.2 Bargaining Power of Buyers
18.3 Bargaining Power of Suppliers
18.4 Degree of Competition
18.5 Threat of New Entrants
18.6 Threat of Substitutes
19. Company Analysis
19.1 Ocular Therapeutix Inc.
19.1.1 Overview
19.1.2 Recent Development
19.1.3 Revenue
19.2 Portola Pharmaceuticals Inc.
19.2.1 Overview
19.2.2 Recent Development
19.2.3 Revenue
19.3 Alcon
19.3.1 Overvie
19.3.2 Recent Development
19.3.3 Revenue
19.4 Santen Pharmaceutical Co., Ltd.
19.4.1 Overview
19.4.2 Recent Development
19.4.3 Revenue
19.5 Novartis
19.5.1 Overview
19.5.2 Recent Developmen
19.5.3 Revenue
List Of Figures:
Figure-01: Global – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-02: Global – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-03: Global – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-04: Global – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-05: Global – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-06: Global – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-07: India – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-08: India – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-09: India – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-10: India – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-11: India – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-12: India – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-13: China – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-14: China – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-15: China – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-16: China – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-17: China – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-18: China – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-19: Japan – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-20: Japan – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-21: Japan – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-22: Japan – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-23: Japan – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-24: Japan – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-25: United States – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-26: United States – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-27: United States – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-28: United States – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-29: United States – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-30: United States – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-31: United Kingdom – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-32: United Kingdom – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-33: United Kingdom – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-34: United Kingdom – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-35: United Kingdom – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-36: United Kingdom – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-37: France – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-38: France – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-39: France – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-40: France – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-41: France – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-42: France – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-43: Germany – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-44: Germany – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-45: Germany – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-46: Germany – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-47: Germany – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-48: Germany – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-49: Italy – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-50: Italy – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-51: Italy – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-52: Italy – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-53: Italy – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-54: Italy – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-55: Spain – Allergic Conjunctivitis Market (Million US$), 2016 – 2021
Figure-56: Spain – Forecast for Allergic Conjunctivitis Market (Million US$), 2022 – 2027
Figure-57: Spain – Allergic Conjunctivitis Patient Numbers (Million), 2016 – 2021
Figure-58: Spain – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 – 2027
Figure-59: Spain – Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 – 2021
Figure-60: Spain – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 – 2027
Figure-61: Disease Type – Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Market (Million US$), 2016 – 2021
Figure-62: Disease Type – Forecast for Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Market (Million US$), 2022 – 2027
Figure-63: Disease Type – Vernal Keratoconjunctivitis (VKC) Market (Million US$), 2016 – 2021
Figure-64: Disease Type – Forecast for Vernal Keratoconjunctivitis (VKC) Market (Million US$), 2022 – 2027
Figure-65: Disease Type – Atopic Keratoconjunctivitis (AKC) Market (Million US$), 2016 – 2021
Figure-66: Disease Type – Forecast for Atopic Keratoconjunctivitis (AKC) Market (Million US$), 2022 – 2027
Figure-67: Disease Type – Giant Papillary Conjunctivitis (GPC) Market (Million US$), 2016 – 2021
Figure-68: Disease Type – Forecast for Giant Papillary Conjunctivitis (GPC) Market (Million US$), 2022 – 2027
Figure-69: Ocular Therapeutix Inc. – Global Revenue (Million US$), 2016 – 2021
Figure-70: Ocular Therapeutix Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-71: Portola Pharmaceuticals Inc. – Global Revenue (Million US$), 2016 – 2021
Figure-72: Portola Pharmaceuticals Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-73: Alcon – Global Revenue (Million US$), 2016 – 2021
Figure-74: Alcon – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-75: Santen Pharmaceutical Co., Ltd. – Global Revenue (Million US$), 2016 – 2021
Figure-76: Santen Pharmaceutical Co., Ltd. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-77: Novartis – Global Revenue (Million US$), 2016 – 2021
Figure-78: Novartis – Forecast for Global Revenue (Million US$), 2022 – 2027
List Of Tables:
Table-01: Global – Allergic Conjunctivitis Market Share by Countries (Percent), 2018 – 2021
Table-02: Global – Forecast for Allergic Conjunctivitis Market Share by Countries (Percent), 2022 – 2027
Table-03: Global – Allergic Conjunctivitis Patients Population Share by Countries (Percent), 2018 – 2021
Table-04: Global – Forecast for Allergic Conjunctivitis Patients Population Share by Countries (Percent), 2022 – 2027
Table-05: Global – Allergic Conjunctivitis Treated Patients Population Share by Countries (Percent), 2018 – 2021
Table-06: Global – Forecast for Allergic Conjunctivitis Treated Patients Population Share by Countries (Percent), 2022 – 2027
Table-07: Global – Allergic Conjunctivitis Market Share by Disease Type (Percent), 2018 – 2021
Table-08: Global – Forecast for Allergic Conjunctivitis Market Share by Disease Type (Percent), 2022 – 2027
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com